Insider Selling: Hims & Hers Health (NYSE:HIMS) Insider Sells 3,461 Shares of Company Stock

Key Points

• Insider sale: Soleil Boughton sold 3,461 Hims & Hers Health shares for approximately $100,577 at an average price of $29.06 under a Rule 10b5-1 plan, retaining 297,348 shares. Boughton has also made several sales since August.
• Stock and financial performance: HIMS rose 6.5% to $29.53, but the company reported a quarterly EPS loss of $0.37, missing estimates, despite revenue of $753.21 million—up 38.2% year over year and above forecasts.
• Analyst and legal backdrop: Analysts maintain a consensus “Hold” rating with an average price target of $32.43, while securities litigation and FTC-related allegations remain key risks that could increase volatility.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 3,461 shares of the business's stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $29.06, for a total value of $100,576.66. Following the completion of the transaction, the insider directly owned 297,348 shares in the company, valued at approximately $8,640,932.88. This trade represents a 1.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, September 30th, Soleil Boughton sold 3,461 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.17, for a total transaction of $100,957.37.
• On Wednesday, September 16th, Soleil Boughton sold 6,236 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.86, for a total transaction of $173,734.96.
• On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.33, for a total transaction of $97,965.14.
• On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05.

Hims & Hers Health Stock Up 6.5%

HIMS traded up $1.81 during midday trading on Thursday, hitting $29.53. The company had a trading volume of 15,936,884 shares, compared to its average volume of 23,095,879. The stock's 50 day moving average price is $29.32 and its 200 day moving average price is $28.66. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $63.63. The company has a market capitalization of $6.89 billion, a price-to-earnings ratio of -46.88 and a beta of 2.44. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.32). The company had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%. Hims & Hers Health's revenue for the quarter was up 38.2% compared to the same quarter last year. During the same period last year, the company earned $0.17 EPS. On average, research analysts anticipate that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Weiss Ratings reissued a "sell (d)" rating on shares of Hims & Hers Health in a research note on Friday, August 7th. Truist Financial upped their target price on Hims & Hers Health from $27.00 to $32.00 and gave the stock a "hold" rating in a research report on Monday, August 24th. TD Cowen increased their target price on Hims & Hers Health from $25.00 to $30.00 and gave the stock a "hold" rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. began coverage on shares of Hims & Hers Health in a research report on Friday, September 11th. They issued a "neutral" rating and a $32.00 price target for the company. Finally, Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, July 1st. Three equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $32.43.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers launched its Hers women’s-health platform in Australia following its acquisition of Eucalyptus, a deal valued at approximately $1.15 billion. The rollout expands Hims’ geographic reach and adds offerings in weight management, hormonal health and hair regrowth, potentially creating new long-term revenue opportunities. Hims & Hers Launches Hers in Australia
• Neutral Sentiment: Multiple law firms issued substantially similar notices reminding investors that November 2, 2026 is the deadline to seek lead-plaintiff status in a securities class action covering purchases made from August 4, 2025, through July 29, 2026. The repeated announcements largely publicize the existing case rather than represent separate lawsuits or new company developments. Kaplan Fox HIMS Class Action Notice
• Negative Sentiment: The securities litigation and FTC-related allegations are the main bearish catalyst. Investors face uncertainty over potential legal costs, regulatory remedies, reputational damage and the effect on customer growth or operating practices. The legal overhang may continue to increase volatility until the allegations are resolved. Hims & Hers Faces Securities Fraud Class Action

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds have recently added to or reduced their stakes in HIMS. MassMutual Private Wealth & Trust FSB increased its stake in Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company's stock valued at $27,000 after buying an additional 319 shares during the last quarter. Sigma Planning Corp boosted its stake in shares of Hims & Hers Health by 1.5% in the 1st quarter. Sigma Planning Corp now owns 26,007 shares of the company's stock worth $540,000 after buying an additional 388 shares during the last quarter. Versant Capital Management Inc boosted its stake in shares of Hims & Hers Health by 801.2% in the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company's stock worth $26,000 after buying an additional 665 shares during the last quarter. BIP Wealth LLC boosted its stake in shares of Hims & Hers Health by 6.0% in the 1st quarter. BIP Wealth LLC now owns 16,278 shares of the company's stock worth $338,000 after buying an additional 915 shares during the last quarter. Finally, D.A. Davidson & CO. grew its holdings in shares of Hims & Hers Health by 5.4% in the first quarter. D.A. Davidson & CO. now owns 19,617 shares of the company's stock valued at $407,000 after acquiring an additional 1,000 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.